Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Propofol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 6/20 | 0.74 |
| ▸ | GABRB1 known ✓ | P18505 | 4/20 | 0.74 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.74 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.74 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.74 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.74 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.74 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.74 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.74 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | CA1 | P00915 | 2/20 | 0.74 |
| ▸ | CA2 | P00918 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | FAAH | O00519 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propofol SCHEMBL4023094 | 0.91 | GABRA1 (0.81) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL13277157 | 0.87 | GABRA1 (0.74) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL2414429 | 0.86 | GABRA1 (1.00) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL36245 | 0.86 | GABRA1 (1.00) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL23277006 | 0.86 | GABRA1 (0.65) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL9052469 | 0.86 | GABRA1 (0.65) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL29792946 | 0.85 | GABRA1 (0.71) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL28223940 | 0.84 | GABRA1 (0.85) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL4088686 | 0.84 | GABRA1 (0.94) | GABRA1GABRB1LMNAGABRB2GABRG2 | |
| Propofol SCHEMBL10968613 | 0.84 | GABRA1 (0.94) | GABRA1GABRB1LMNAGABRB2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312424-A1 | AROMATIC PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090286763-A1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7576127-B2 | Aromatic prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7550506-B2 | Amino acid derived prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1781596-B1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7230003-B2 | Aromatic prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1781596-A1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060287525-A1 | Aromatic prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060100160-A1 | Amino acid derived prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006017352-A1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20050107385-A1 | Aromatic prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023204-A2 | AROMATIC PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312424-A1 | AROMATIC PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | CYP2C19, CYP3A5, CYP2C9 | GABRA1 365/4885GABRB1 373/4885GABRB2 377/4885 |
| US-20060100160-A1 | Amino acid derived prodrugs of propofol, compositions and uses thereof | SLC1A1, SLC1A5, SLC1A2 | GABRA1 144/4885GABRB1 230/4885GABRB2 228/4885 |
| US-20050107385-A1 | Aromatic prodrugs of propofol, compositions and uses thereof | CYP2C19, CYP3A5, CYP2C9 | GABRA1 365/4885GABRB1 373/4885GABRB2 377/4885 |
| US-20060287525-A1 | Aromatic prodrugs of propofol, compositions and uses thereof | CYP2C19, CYP3A5, CYP2C9 | GABRA1 365/4885GABRB1 373/4885GABRB2 377/4885 |
| US-20090286763-A1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | SLC1A1, SLC1A5, SLC1A2 | GABRA1 144/4885GABRB1 230/4885GABRB2 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.